EZH2 and Miyoshi myopathy: Relapsed and/or refractory MM patients were included in one of these trials, which studied the safety and clinical activity of EZH2 inhibitor GSK126 (GSK2816126), although this trial was terminated because of insufficient evidence of clinical activity (NCT02082977).